TURNOVER (x1000 SEK)
NET PROFIT (x1000 SEK)
EMPLOYEES
Rechon Life Science AB
Closing information (x1000 SEK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
557,628
|
485,933
|
388,250 |
| Financial expenses |
3,943
|
3,130
|
1,296 |
| Earnings before taxes |
59,166
|
56,429
|
60,255 |
| EBITDA |
81,860
|
78,704
|
77,836 |
| Total assets |
486,410
|
364,324
|
326,949 |
| Current assets |
267,475
|
204,989
|
168,267 |
| Current liabilities |
143,689
|
100,878
|
79,819 |
| Equity capital |
249,447
|
202,962
|
169,669 |
| - share capital |
27,541
|
27,541
|
27,541 |
| Employees (average) |
286
|
249
|
212 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
51.3%
|
55.7%
|
51.9% |
| Turnover per employee |
1,950
|
1,952
|
1,831 |
| Profit as a percentage of turnover |
10.6%
|
11.6%
|
15.5% |
| Return on assets (ROA) |
13.0%
|
16.3%
|
18.8% |
| Current ratio |
186.1%
|
203.2%
|
210.8% |
| Return on equity (ROE) |
23.7%
|
27.8%
|
35.5% |
| Change turnover |
71,695
|
97,683
|
82,600 |
| Change turnover % |
15%
|
25%
|
27% |
| Chg. No. of employees |
37
|
37
|
28 |
| Chg. No. of employees % |
15%
|
17%
|
15% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.